SOPHiA DDM™ Community CLL Clonality Solution is an all-in-one application developed and tested by European Hemato-Oncology experts within the SOPHiA GENETICS Community for the analysis and stratification of CLL cases. This sample-to-report approach combines an optimized next-generation sequencing (NGS) workflow and the powerful analytics of the SOPHiA DDM™ Platform.
In this study, we demonstrate the effectiveness of the SOPHiA DDM™ application in generating a comprehensive report on the genomic status of CLL in a fictitious case. Download the application note and learn more about the SOPHiA DDM™ Community Clonality Solution CLL.
[dgat_layout_shortcode id="281412"]
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.